Today Biogen Idec (BIIB) reported top-line results of EMPOWER, a Phase 3 trial investigating dexpramipexole in people with amyotrophic lateral sclerosis (ALS).
FORBES: Biogen Idec ALS Drug Fails
2.
Deciding to bet on dexpramipexole, an experimental drug for ALS, was one of the f irst bets made by Biogen Idec chief executive George Scangos when he arrived at the company.